Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Esperion Therapeutics reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking a surprise of -77.78% [1] - The company achieved revenues of $87.31 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.75% and showing significant growth from $51.63 million a year ago [2] - Esperion's stock has increased by approximately 33.6% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for Esperion is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.10 on revenues of $137.02 million, and for the current fiscal year at -$0.05 on revenues of $365.54 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Esperion's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]